Key Points
- Insider sales: Director Jula Inrig sold 2,031 shares on Jan 5 at $40.18 (~$81,605) and also sold 445 shares on Jan 6 and 15,000 shares on Dec 24, totaling 17,476 shares for roughly $728,400, cutting her stake to 86,756 shares (a 2.29% ownership decline).
- Company results and sentiment: Travere beat expectations with Q earnings of $0.28 EPS and $164.9M revenue (up 162% YoY) but still posts a negative net margin and ROE; analysts hold a consensus "Moderate Buy" with an average target of $38.71 and the stock trading near its 12‑month high.
Travere Therapeutics, Inc. (NASDAQ:TVTX - Get Free Report) insider Jula Inrig sold 445 shares of the company's stock in a transaction on Tuesday, January 6th. The stock was sold at an average price of $37.75, for a total transaction of $16,798.75. Following the transaction, the insider owned 86,311 shares of the company's stock, valued at approximately $3,258,240.25. The trade was a 0.51% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link.
Jula Inrig also recently made the following trade(s):
- On Monday, January 5th, Jula Inrig sold 2,031 shares of Travere Therapeutics stock. The stock was sold at an average price of $40.18, for a total transaction of $81,605.58.
- On Wednesday, December 24th, Jula Inrig sold 15,000 shares of Travere Therapeutics stock. The stock was sold at an average price of $42.00, for a total transaction of $630,000.00.
Travere Therapeutics Price Performance
Shares of TVTX opened at $36.28 on Thursday. Travere Therapeutics, Inc. has a twelve month low of $12.91 and a twelve month high of $42.13. The stock's 50 day moving average is $35.61 and its two-hundred day moving average is $25.67. The firm has a market capitalization of $3.25 billion, a PE ratio of -34.23, a P/E/G ratio of 1.26 and a beta of 0.85. The company has a current ratio of 2.75, a quick ratio of 2.71 and a debt-to-equity ratio of 4.23.
Travere Therapeutics (NASDAQ:TVTX - Get Free Report) last issued its earnings results on Thursday, October 30th. The company reported $0.28 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.31) by $0.59. Travere Therapeutics had a negative return on equity of 178.68% and a negative net margin of 20.32%.The business had revenue of $164.86 million during the quarter, compared to the consensus estimate of $106.09 million. During the same period in the prior year, the business posted ($0.70) EPS. The company's revenue for the quarter was up 162.1% on a year-over-year basis. Research analysts anticipate that Travere Therapeutics, Inc. will post -1.4 earnings per share for the current year.
Institutional Trading of Travere Therapeutics
Institutional investors and hedge funds have recently modified their holdings of the business. Vanguard Group Inc. increased its stake in shares of Travere Therapeutics by 10.3% during the 3rd quarter. Vanguard Group Inc. now owns 6,613,368 shares of the company's stock worth $158,059,000 after purchasing an additional 619,085 shares in the last quarter. Adage Capital Partners GP L.L.C. lifted its stake in Travere Therapeutics by 27.4% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 2,784,000 shares of the company's stock valued at $41,203,000 after buying an additional 599,102 shares in the last quarter. Emerald Advisers LLC grew its holdings in Travere Therapeutics by 2.6% during the 3rd quarter. Emerald Advisers LLC now owns 2,146,767 shares of the company's stock valued at $51,308,000 after buying an additional 55,407 shares during the last quarter. Geode Capital Management LLC increased its position in Travere Therapeutics by 1.4% during the second quarter. Geode Capital Management LLC now owns 2,003,701 shares of the company's stock worth $29,658,000 after buying an additional 27,040 shares in the last quarter. Finally, Stephens Investment Management Group LLC purchased a new position in Travere Therapeutics during the third quarter worth $38,232,000.
Analyst Ratings Changes
Several brokerages have commented on TVTX. Weiss Ratings restated a "sell (e+)" rating on shares of Travere Therapeutics in a research report on Wednesday, October 8th. Wells Fargo & Company raised their price objective on shares of Travere Therapeutics from $27.00 to $35.00 and gave the company an "overweight" rating in a research note on Thursday, September 11th. Cowen restated a "buy" rating on shares of Travere Therapeutics in a research report on Friday, October 31st. Zacks Research cut shares of Travere Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Wednesday, November 12th. Finally, Stifel Nicolaus boosted their price target on Travere Therapeutics from $20.00 to $25.00 and gave the stock a "hold" rating in a research note on Friday, September 12th. Thirteen analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Travere Therapeutics has a consensus rating of "Moderate Buy" and a consensus target price of $38.71.
Check Out Our Latest Stock Analysis on Travere Therapeutics
Travere Therapeutics Company Profile
(
Get Free Report)
Travere Therapeutics, Inc (NASDAQ: TVTX) is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company's mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.
The company's lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
